Trojan horse obesity drug boosts weight loss in mice

May 08, 2026

Iniulat ng AI

Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.

Researchers at Helmholtz Munich created the compound by linking an incretin-based molecule with lanifibranor, a pan-PPAR agonist. The design functions like a Trojan horse, allowing the additional drug to enter cells via GLP-1 or GIP receptors before activating switches that regulate fat and sugar metabolism inside the nucleus.

Mga Kaugnay na Artikulo

Medical team discussing integrated obesity care with GLP-1 drugs, endoscopy, surgery and precision medicine.

Updated POWER framework urges multidisciplinary obesity care beyond GLP-1 drugs

June 20, 2026 Iniulat ng AI Larawang ginawa ng AI Fact checked

A new Gastroenterology commentary revisits the American Gastroenterological Association’s 2017 POWER framework, arguing that GLP-1 medicines should be integrated with endoscopic therapies, bariatric surgery and precision medicine to improve long-term obesity outcomes.

Oral GLP-1 pill shows strong results in diabetes trial

A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

May 08, 2026 Iniulat ng AI Fact checked

A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.

Health

Study links Ozempic to lower depression and anxiety risks

Asia

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

Health

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Study finds GLP-1 hormone at very low levels in arthritic joint fluid

Researchers at Aarhus University report that the hormone GLP-1—mimicked by drugs such as Wegovy—can be measured in the joint fluid of patients with inflammatory arthritis, but only at very low levels. The findings, published in The Lancet Rheumatology, suggest GLP-1–based medicines might eventually be studied for potential direct effects on joint inflammation, though the researchers say clinical trials are needed to show whether such treatment works.

Study links PAM gene variants to weaker blood-sugar response to GLP-1 drugs such as Ozempic

June 05, 2026 Iniulat ng AI Fact checked

Researchers say genetic variants in the PAM gene may help explain why some people with Type 2 diabetes get less blood-sugar benefit from GLP-1 receptor agonist drugs such as Ozempic, a phenomenon they describe as “GLP-1 resistance.”

June 14, 2026 20:53